Serratus Posterior Plane Block vs Erector Spine Plane Block

NCT07021131 | Not Yet Recruiting

• 1 other identifier: SERRATUS
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

Analgesia related to the administration of local anesthetic solution into the fascia of erector spinae muscle is mediated by the effect of local anesthetic on the posterior and lateral branches of the anterior part of the spinal nerve. Comparable analgesic efficiency after the administration of both nerve blocks would reject the widespread theory of the paravertebral site of effect of the local anesthetic in ESPB.

Conditions

Regional Anesthesia

Outcome Measures

Primary Outcomes (1)

• Cumulative opioid dose in 72 hours

  Irrespective of the type of the block, 20 mls of 0.25 % bupivacaine will be administered to the block catether every 8 hours. Every patients will receive non-opioid analgesics according to standardized ward guideline. VAS score is recorded at least every 3 hours (except for time patient is asleep). Any time patient reports VAS score \>=5, he/she will receive 5 mg of morphine intravenously (or equivalent dose of Oxycodone per os). Cumulative dose of opioids will be recorded.

  from end of surgery to 72 hours after the end surgery

Study Arms (2)

Erector spinae plane block

NO INTERVENTION

Patients undergoing VATS with the use of continuous peripheral nerve block type A.

Serratus Posterior Plane Block

EXPERIMENTAL

Patients undergoing general anaesthesia with continuous peripheral block type B.

Procedure: new type of peripheral block Serratus Posterior Plane Block

Interventions

new type of peripheral block Serratus Posterior Plane Block PROCEDURE

Intervention will be Serratus Posterior Plane Block.

Serratus Posterior Plane Block

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patiens undergoing VATS-surgery

You may not qualify if:

• Age \< 20 years
• Body Mass Index \>35 kg/m2
• Technical difficulties with the nerve block administration and/or subsequent bolus application
• Abnormal course of the surgery (e.g. conversion to thoracotomy) or the postoperative phase (e.g. surgical revision of the chest)
• Patient's refusal

Sponsors & Collaborators

• Masarykova Nemocnice v Usti nad Labem, Krajska Zdravotni a.s.: lead

Study Sites (1)

Krajská zdravotní, a.s. - Masarykova nemocnice v Ústí nad Labem, o.z.

Ústí nad Labem, Ústecký kraj, 40011, Czechia

Location

Study Officials

• Miroslava Korfova

  Krajská zdravotní, a.s. - Masarykova nemocnice v Ústí nad Labem, o.z.

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Daniel Nalos

CONTACT

+420737230792; nalosdan@seznam.cz

Ondrej Maly

CONTACT

+420774145512; ondrej.maly@kzcr.eu

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: senior researcher

Study Record Dates

• First Submitted: May 19, 2025
• First Posted: June 13, 2025
• Study Start: July 1, 2025
• Primary Completion: December 1, 2025
• Study Completion (Estimated): July 1, 2026
• Last Updated: June 13, 2025

Record last verified: 2025-06

Locations

CZ (1)